Phillip Frost Updates BioCardia Stake via Frost Gamma Trust

TL;DR

**Phillip Frost just updated his BioCardia stake, watch for potential insider moves!**

AI Summary

Phillip Frost, M.D., through Frost Gamma Investments Trust, filed an SC 13D/A on February 6, 2024, updating his beneficial ownership in BioCardia, Inc. This amendment, dated January 19, 2024, indicates a change in his holdings of BioCardia's Common Stock, par value $.001 per share. This matters to investors because it signals a significant insider's updated position, which can influence market perception and potentially indicate future strategic moves for the company.

Why It Matters

This filing shows an update to a major insider's ownership, which can be a strong signal to the market about the company's future prospects or potential strategic shifts.

Risk Assessment

Risk Level: medium — While an insider update isn't inherently risky, the details of the change (which aren't fully disclosed in this snippet) could signal either positive or negative developments for the stock.

Analyst Insight

Investors should monitor subsequent filings from Phillip Frost, M.D. or Frost Gamma Investments Trust for specific details on changes in share count or ownership percentage, as this filing only indicates an update occurred.

Key Players & Entities

• Phillip Frost, M.D. (person) — Reporting Person and beneficial owner of BioCardia, Inc. shares
• Frost Gamma Investments Trust (company) — Entity through which Phillip Frost, M.D. holds shares and is the filing person
• BioCardia, Inc. (company) — Subject company whose securities are being reported
• $0.001 (dollar_amount) — Par value per share of BioCardia, Inc. Common Stock
• January 19, 2024 (date) — Date of the event requiring the filing of this statement
• February 6, 2024 (date) — Date the SC 13D/A was filed

Forward-Looking Statements

• Phillip Frost, M.D. will continue to be a significant beneficial owner of BioCardia, Inc. (Phillip Frost, M.D.) — high confidence, target: 2025-02-06

FAQ

Key Financial Figures

• $0.38 — multiple trades at prices ranging from $0.38 to $0.57 in the open market. The previo
• $0.57 — trades at prices ranging from $0.38 to $0.57 in the open market. The previously disc
• $6.75 — held by FGIT with an exercise price of $6.75 and 111,111 shares of Common Stock unde

Filing Documents

• tm245362d1_sc13da.htm (SC 13D/A) — 48KB
• tm245362d1_ex1.htm (EX-1) — 5KB
• 0001104659-24-011115.txt ( ) — 55KB

is hereby amended and restated in its entirety to read as follows

Item 4 is hereby amended and restated in its entirety to read as follows: The information set forth or incorporated under the heading "Explanatory Note" and in Items 2, 3 and 5 is incorporated by reference in its entirety into this Item 4. Each of the Reporting Persons may, at any time or from time to time, formulate plans or proposals regarding the Issuer or its securities to the extent deemed advisable by the Reporting Persons in light of each of their general investment policies, market conditions, subsequent developments affecting the Issuer, the general business and future prospects of the Issuer, or other factors. The Reporting Persons intend to review their investments in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, actions taken by the board of directors, price levels of shares of the Common Stock, other investment opportunities available to the Reporting Persons, concentration of positions in the portfolios managed by the Reporting Persons, market conditions and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investments in the Issuer as they deem appropriate, including, without limitation, purchasing additional shares of the Common Stock or other financial instruments related to the Issuer or selling some or all of their beneficial or economic holdings, engaging in hedging or similar transactions with respect to the securities relating to the Issuer and/or otherwise changing their intention with respect to any and all matters referred to in Item 4 of Schedule 13D. Except as disclosed herein, none of the Reporting Persons has any plans or proposals which relate to or which would result in any of the actions specified in this paragraph of Item 4 of Schedule 13D. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER Items 5(a)-(b) are hereby amended and restated to read as follows:

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of each of the undersigned's knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct. Date: February 6, 2024 Dr. Phillip Frost By: /s/ Phillip Frost, M.D. Frost Gamma Investments Trust By: /s/ Phillip Frost, M.D. Phillip Frost, M.D. Trustee

View Full Filing

View this SC 13D/A filing on SEC EDGAR